Targacept is a clinical-stage biopharmaceutical company engaged in developing a varied pipeline of innovative NNR therapeutics for hard-to-treat nervous system diseases and disorders. The company’s clinical pipeline includes multiple Phase 2 product candidates that all represent first-in-class opportunities, and Targacept is leveraging its scientific leadership-diverse pipeline to attract noteworthy collaborations with worldwide pharmaceutical companies. For more information, visit the company’s at www.targacept.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: